YP
YP1A.F Immutep Limited
- Market cap
- EUR 1.52M
- P/E
- -
- P/B
- 0.60x
- ROE
- -128.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is YP1A.F undervalued?
Graham numberThe Graham number of Immutep Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Immutep Limited fundamental analysis
No fundamental analysis for Immutep Limited yet.
Immutep Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Immutep Limited
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment …
Full company profileImmutep Limited financial statements
Immutep Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 2.63M | 140K | 7.49M | 120K | 248K | 170K | 0.00 | 14.6M |
| Operating Income | -9.46M | -11.7M | -19.0M | -15.1M | -19.7M | -49.2M | -41.4M | -46.6M | -81.6M |
| EBITDA | -8.40M | -10.9M | -17.1M | -11.4M | -29.9M | -43.7M | -39.9M | -42.7M | -79.2M |
| Net Income | -9.37M | -12.7M | -18.3M | -13.5M | -29.9M | -46.8M | -39.9M | -42.7M | -79.3M |
| EPS | -0.04 | -0.04 | -0.05 | -0.03 | -0.04 | -0.05 | -0.03 | -0.03 | -0.05 |
| Balance Sheet | |||||||||
| Total Assets | 35.0M | 47.0M | 40.5M | 46.6M | 82.0M | 149M | 147M | 202M | 83.3M |
| Total Liabilities | 8.43M | 13.5M | 16.2M | 13.3M | 8.76M | 11.8M | 11.0M | 12.1M | 21.7M |
| Shareholders' Equity | 26.5M | 33.5M | 24.4M | 33.3M | 73.3M | 137M | 136M | 190M | 61.5M |
| Cash & Short-term Investments | 12.2M | 23.5M | 16.6M | 26.3M | 60.1M | 116M | 123M | 162M | 63.7M |
| Cash Flow | |||||||||
| Operating Cash Flow | -8.51M | -7.78M | -15.3M | -10.8M | -17.6M | -30.2M | -35.4M | - | - |
| Capital Expenditure | 6.64K | 11.9K | 41.4K | 19.3K | 15.6K | 22.9K | 82.7K | 932K | 92.9K |
| Free Cash Flow | -8.51M | -7.79M | -15.3M | -10.9M | -17.7M | -44.0M | -35.9M | -35.8M | -55.6M |
| Ratios | |||||||||
| ROE | -35.3% | -38.0% | -75.2% | -40.4% | -40.8% | -34.2% | -29.2% | -22.5% | -128.9% |
| ROA | -26.8% | -27.1% | -45.2% | -28.9% | -36.5% | -31.5% | -27.1% | -21.2% | -95.2% |
| Net Profit Margin | - | -484.6% | -13,123.3% | -179.9% | -24,929.0% | -18,906.5% | -23,417.6% | - | -544.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Immutep Limited dividends
Immutep Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 0.05:1 on Sep 28, 2026.
Who owns Immutep Limited
- Insiders 0.01%
- Institutions 1.13%
- Public & others 98.86%
- Shares outstanding 7.37M
- Free float 6.89M
Immutep Limited company profile
- Company name
- Immutep Limited
- Ticker
- YP1A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Australia Square, Sydney, NSW, Australia, 2000
- Phone
- 61 2 8315 7003
- Website
- immutep.com
About Immutep Limited
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Immutep Limited management
5- Mr. Marc VoigtCEO, MD, CFO, Chief Business Officer & Executive Director · born 1973
- Ms. Deanne Miller LLBCOO, General Counsel & Joint Company Secretary · born 1977
- Mr. Christian Mueller BBA, MSc.Chief Development Officer
- Dr. Stephan Winckels M.D., Ph.D.Chief Medical Officer
- Ms. Indira NaiduJoint Company Secretary